Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. Chen XC, et al. Lancet Oncol. 2025 Jan;26(1):27-36. doi: 10.1016/S1470-2045(24)00581-3. Epub 2024 Nov 26. Lancet Oncol. 2025. PMID: 39612919 Clinical Trial.
Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021.
Jiao DC, Zhu JJ, Qin L, Guo XH, Zhao YJ, Chen XC, Wang CZ, Lu ZD, Li LF, Cui SD, Liu ZZ; Chinese Society of Breast Surgery. Jiao DC, et al. Among authors: chen xc. Chin Med J (Engl). 2021 Apr 1;134(8):895-897. doi: 10.1097/CM9.0000000000001412. Chin Med J (Engl). 2021. PMID: 33813515 Free PMC article. No abstract available.
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer.
Zhu J, Jiao D, Yan M, Chen X, Wang C, Lu Z, Li L, Sun X, Qin L, Guo X, Zhang C, Qiao J, Li J, Fan Z, Wang H, Zhang J, Yin Y, Fu P, Geng C, Jin F, Jiang Z, Cui S, Liu Z. Zhu J, et al. Front Oncol. 2021 Apr 29;11:675070. doi: 10.3389/fonc.2021.675070. eCollection 2021. Front Oncol. 2021. PMID: 33996607 Free PMC article.
Clinical practice guidelines for multigene assays in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Zhu JJ, Jiao DC, Yan M, Guo XH, Zhao YJ, Chen XC, Wang CZ, Lu ZD, Li LF, Cui SD, Liu ZZ; Chinese Society of Breast Surgery. Zhu JJ, et al. Among authors: chen xc. Chin Med J (Engl). 2021 Sep 21;134(19):2269-2271. doi: 10.1097/CM9.0000000000001409. Chin Med J (Engl). 2021. PMID: 34561332 Free PMC article. No abstract available.
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Orlandi A, Ishii N, Takabe K, Franceschini G, Ricci F, Verschraegen C, Liu Z, Zhang M, Lv H, Liu L, Yang X, Xiao H, Gao Z, Li X, Dong F, Chen X, Qiao J, Zhang G. Yan M, et al. Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31. Lancet Oncol. 2022. PMID: 35085506 Clinical Trial.
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu Z, Wang C, Chen X, Zhu J, Sun X, Xia Q, Lu Z, Qiao J, Zhou Y, Wang H, Wang Y, Yan M. Liu Z, et al. Eur J Cancer. 2022 Apr;165:157-168. doi: 10.1016/j.ejca.2022.01.022. Epub 2022 Feb 27. Eur J Cancer. 2022. PMID: 35235873 Free article. Clinical Trial.
601 results